These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23812682)

  • 1. Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment.
    Spagnuolo V; Cocorullo D; Galli L; Bigoloni A; Galli A; Rubinacci A; Mignogna G; Carbone A; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2013 Dec; 68(12):2960-3. PubMed ID: 23812682
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients.
    Domingo P; Lamarca MK; Gallego-Escuredo JM; Torres F; Domingo JC; Villarroya J; Gutierrez Mdel M; Mateo MG; Vidal F; Villarroya F; Giralt M
    J Antimicrob Chemother; 2015; 70(6):1825-32. PubMed ID: 25700720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 4. Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs.
    Ceperuelo-Mallafré V; Escoté X; Viladés C; Peraire J; Domingo P; Solano E; Sirvent JJ; Pastor R; Tinahones F; Leal M; Richart C; Vendrell J; Vidal F; ; Alba V; Aguilar A; Auguet T; Chacón MR; López-Dupla M; Megia A; Miranda M; Olona M; Saurí A; Vargas M; Velasco I; Veloso S; Fontanet A; Gutiérrez M; Mateo G; Muñoz J; Sambeat MA
    HIV Med; 2012 May; 13(5):297-303. PubMed ID: 22256965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic disorders and cardiovascular risk factors observed in patients infected by the HIV with antiretroviral therapy in Burkina Faso].
    Bognounou R; Diendéré A; Diallo I; Tieno H; Guira O; Ouedraogo DD; Drabo YJ
    Med Trop (Mars); 2011 Dec; 71(6):626-7. PubMed ID: 22393637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cardiovascular events predicted by the Rama-EGAT score among HIV-infected patients in Thailand.
    Suppadungsuk S; Yamwong S; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Sep; 44(5):818-24. PubMed ID: 24437317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapy.
    Boccara F; Ederhy S; Janower S; Benyounes N; Odi G; Cohen A
    HIV Med; 2005 Jul; 6(4):240-4. PubMed ID: 16011528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy.
    Kristoffersen US; Kofoed K; Kronborg G; Giger AK; Kjaer A; Lebech AM
    HIV Med; 2009 Feb; 10(2):79-87. PubMed ID: 19200170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular involvements in HIV-infected patients.
    Alharethi R
    Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1227-35. PubMed ID: 23972010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.
    Seiler S; Reichart B; Roth D; Seibert E; Fliser D; Heine GH
    Nephrol Dial Transplant; 2010 Dec; 25(12):3983-9. PubMed ID: 20525642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
    Dominguez S; Ghosn J; Peytavin G; Guiguet M; Tubiana R; Valantin MA; Murphy R; Bricaire F; Benhamou Y; Katlama C
    J Antimicrob Chemother; 2010 Nov; 65(11):2445-9. PubMed ID: 20813809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients.
    Dabrowska MM; Mikula T; Wiercinska-Drapalo A
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1308-12. PubMed ID: 22825646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The search for biomarkers of immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy.
    Oliver BG; Price P
    Biomark Med; 2011 Apr; 5(2):149-54. PubMed ID: 21473718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV.
    Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
    Clin Infect Dis; 2013 Jul; 57(2):314-21. PubMed ID: 23575194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
    Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G
    Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
    Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
    J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone and bone mineral densitiy in HIV-1-infected male subjects.
    Teichmann J; Lange U; Discher T; Lohmeyer J; Stracke H; Bretzel RG
    Eur J Med Res; 2008 Apr; 13(4):173-8. PubMed ID: 18504173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.
    Boccara F
    AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.